FDA Issues Early Communication about Ongoing Safety Review of Orlistat. Weight loss drug review includes both prescription drug Xenical and OTC drug Alli. The U.S. Food […]
FDA’s Early Communication about the Ongoing Safety Review of Orlistat. FDA is reviewing new safety information regarding reports of liver-related adverse events in patients taking orlistat. […]
Dietary Supplements Linked to One Death; Pose Risk of Liver Injury. The U.S. Food and Drug Administration is warning consumers to immediately stop using Hydroxycut products […]
Today, Genentech, the manufacturer of the psoriasis drug Raptiva (efalizumab), announced that it has begun a voluntary, phased withdrawal of the product from the U.S. market. […]
Agency Investigating Dilantin Risks of SJS and TEN FDA is investigating new preliminary data regarding a potential increased risk of serious skin reactions including Stevens Johnson […]
Class A Recall – Polar Care – Medical & Radiation Emitting Device Recalls Date Posted August 20, 2008 Recall Number N-0015-2008 Product BREG’s Polar Care 500, […]
Information for Healthcare Professionals: Fluoxetine (marketed as Prozac) FDA ALERT [7/2006]: Increased Risk of Neonatal Persistent Pulmonary Hypertension A recently published case-control study has […]
Biogen Idec and Elan announced on March 22, 2006, that the Food and Drug Administration (FDA) had extended the regulatory review period for the reintroduction of […]